181 related articles for article (PubMed ID: 25495491)
1. Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
Hershman DL
N Engl J Med; 2015 Jan; 372(5):477-8. PubMed ID: 25495491
[No Abstract] [Full Text] [Related]
2. Exemestane with ovarian suppression in premenopausal breast cancer.
Prasad V
N Engl J Med; 2014 Oct; 371(14):1358. PubMed ID: 25271613
[No Abstract] [Full Text] [Related]
3. Exemestane with ovarian suppression in premenopausal breast cancer.
Chlebowski RT; Pan K
N Engl J Med; 2014 Oct; 371(14):1358. PubMed ID: 25271612
[No Abstract] [Full Text] [Related]
4. Exemestane with ovarian suppression in premenopausal breast cancer.
Amoroso V; Berruti A; Simoncini E
N Engl J Med; 2014 Oct; 371(14):1357. PubMed ID: 25271611
[No Abstract] [Full Text] [Related]
5. Exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Francis PA; ;
N Engl J Med; 2014 Oct; 371(14):1358-9. PubMed ID: 25271610
[No Abstract] [Full Text] [Related]
6. Hormone therapy in premenopausal women with early-stage breast cancer.
Rugo HS
N Engl J Med; 2014 Jul; 371(2):175-6. PubMed ID: 25006724
[No Abstract] [Full Text] [Related]
7. Adjuvant ovarian suppression in premenopausal breast cancer.
Montemurro F; Perrone F; Geuna E
N Engl J Med; 2015 Apr; 372(17):1672-3. PubMed ID: 25901438
[No Abstract] [Full Text] [Related]
8. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF
N Engl J Med; 2015 Apr; 372(17):1673. PubMed ID: 25901437
[No Abstract] [Full Text] [Related]
9. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Burstein HJ; Griggs JJ
J Clin Oncol; 2012 Mar; 30(7):684-6. PubMed ID: 22271478
[No Abstract] [Full Text] [Related]
10. Anti-Hormonal Therapies for Premenopausal Patients--What did we Learn from the TEXT/SOFT Trials?
Valsecchi ME; Recondo G; de la Vega M; Greco M; Recondo G; Díaz Cantón E
Rev Recent Clin Trials; 2015; 10(2):90-100. PubMed ID: 26216437
[TBL] [Abstract][Full Text] [Related]
11. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE
Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
[TBL] [Abstract][Full Text] [Related]
12. Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Ingle JN
Steroids; 2011 Jul; 76(8):765-7. PubMed ID: 21382394
[TBL] [Abstract][Full Text] [Related]
13. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
Mouridsen HT
J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
[No Abstract] [Full Text] [Related]
14. Exemestane or tamoxifen?
Atkins CD
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
[No Abstract] [Full Text] [Related]
15. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
16. Update: a 62-year-old woman with a new diagnosis of breast cancer.
Farag N; Burns R; Come SE
JAMA; 2008 Mar; 299(9):1055-6. PubMed ID: 18319415
[No Abstract] [Full Text] [Related]
17. Everolimus in HR-positive advanced breast cancer.
Tartarone A; Lerose R; Aieta M
N Engl J Med; 2012 May; 366(18):1739; author reply 1739-40. PubMed ID: 22551140
[No Abstract] [Full Text] [Related]
18. Everolimus in HR-positive advanced breast cancer.
Massarweh S; Croley J; Weiss H
N Engl J Med; 2012 May; 366(18):1738-9; author reply 1739-40. PubMed ID: 22551139
[No Abstract] [Full Text] [Related]
19. [New results of endocrine therapy of breast cancer (the role of Aromasin)].
Semiglazov VF; Semiglazov VV; Klemtsel' AA; Barash NIu; Zhil'tsova EK; Bozhok AA; Mel'nikova OA; Paltuev RM; Dashian GA; Petrovskiĭ SG; Ivanov VG; Tonuzov EE; Berstein LM
Vopr Onkol; 2004; 50(6):729-36. PubMed ID: 15755074
[No Abstract] [Full Text] [Related]
20. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
[Next] [New Search]
